Clinical Trial: The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Randomized, Double Blind, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of PF-03654764 +/- Allegra (Fexofenadine) On Symptoms Of Allergic Rhinitis
Brief Summary: PF-03654764 should reduce the symptoms of allergic rhinitis. In this study patients will be exposed to pollen and their symptoms observed.
Detailed Summary:
Sponsor: Pfizer
Current Primary Outcome:
- Congestion scores [ Time Frame: 6 hours ]
- Other allergic rhinitis symptoms [ Time Frame: 6 hours ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Pharmacokinetics [ Time Frame: 6 hours ]
- Blood pressure/pulse rate [ Time Frame: 6 hours ]
- Adverse event reporting [ Time Frame: 2 months ]
Original Secondary Outcome: Same as current
Information By: Pfizer
Dates:
Date Received: December 14, 2009
Date Started: January 2010
Date Completion:
Last Updated: August 16, 2010
Last Verified: August 2010